- Home
- RL vs NEUP Comparison
RL vs NEUP Comparison
Compare RL & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RL
- NEUP
- Stock Information
- Founded
- RL 1967
- NEUP 1996
- Country
- RL United States
- NEUP United States
- Employees
- RL N/A
- NEUP N/A
- Industry
- RL Apparel
- NEUP
- Sector
- RL Consumer Discretionary
- NEUP
- Exchange
- RL Nasdaq
- NEUP Nasdaq
- Market Cap
- RL 17.7B
- NEUP 17.4B
- IPO Year
- RL 1997
- NEUP N/A
- Fundamental
- Price
- RL $277.67
- NEUP $4.88
- Analyst Decision
- RL Buy
- NEUP Strong Buy
- Analyst Count
- RL 11
- NEUP 1
- Target Price
- RL $298.10
- NEUP $21.00
- AVG Volume (30 Days)
- RL 821.2K
- NEUP 1.6M
- Earning Date
- RL 02-06-2025
- NEUP 02-14-2025
- Dividend Yield
- RL 1.19%
- NEUP N/A
- EPS Growth
- RL 24.59
- NEUP N/A
- EPS
- RL 10.92
- NEUP N/A
- Revenue
- RL $6,949,600,000.00
- NEUP $662,715.00
- Revenue This Year
- RL $6.67
- NEUP N/A
- Revenue Next Year
- RL $4.07
- NEUP N/A
- P/E Ratio
- RL $25.43
- NEUP N/A
- Revenue Growth
- RL 5.23
- NEUP N/A
- 52 Week Low
- RL $155.96
- NEUP $2.12
- 52 Week High
- RL $289.33
- NEUP $15.72
- Technical
- Relative Strength Index (RSI)
- RL 63.56
- NEUP N/A
- Support Level
- RL $262.93
- NEUP N/A
- Resistance Level
- RL $289.12
- NEUP N/A
- Average True Range (ATR)
- RL 8.04
- NEUP 0.00
- MACD
- RL 1.05
- NEUP 0.00
- Stochastic Oscillator
- RL 78.27
- NEUP 0.00
About RL Ralph Lauren Corporation
Founded by designer Ralph Lauren in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.